A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease

  • Bertram, Kelly (Primary Chief Investigator (PCI))
  • Burn, Katherine, (Project Manager)

Project: Research

StatusActive
Effective start/end date22/11/1930/11/21

Keywords

  • Neuroscience
  • Parkinson's disease
  • Clinical trial